ConductScience.org, home

Trial · NCT07897201

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryIncidence and severity of ecchymosis assessed from standardized digital photographsDay 7 after contraceptive implant insertion or removal
Number of participants in each ecchymosis severity grade at the implant insertion or removal site, assessed by two independent outcome assessors blinded to allocation using standardized digital photographs that include a transparent ruler sticker for scale. Severity is graded by the measured area of discoloration: None (no visible ecchymosis), Mild (less than 1 cm²), Moderate (1 to 3 cm²), or Severe (more than 3 cm²). Higher grades indicate worse bruising. Incidence of ecchymosis is defined as any grade other than None. When the two assessors' area measurements differ by 10% or more, a consensus measurement is used.
SecondaryPain intensity assessed using the Numeric Rating Scale (NRS)15 minutes and 60 minutes after the procedure
Participant-reported pain at the procedure site measured with the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate worse pain.
SecondaryDuration of anesthesia, measured as time to first postoperative analgesic useFrom the end of the procedure up to 24 hours after the procedure
Time in minutes from the end of the procedure to the first use of any pain-relief medication, as reported by the participant through the hospital's LINE Official Account on the evening of the procedure day. Longer times indicate longer-lasting anesthesia. Participants who do not use any pain-relief medication are censored at 24 hours.
SecondaryNumber of participants with bleeding at the procedure siteFrom the procedure through Day 7 after the procedure
Number of participants with any bleeding at the implant insertion or removal site after the procedure, either reported by the participant through the hospital's LINE Official Account or identified by the study team on submitted photographs of the procedure site. Bleeding is defined as visible fresh blood or blood oozing from the procedure site after the participant leaves the clinic.
SecondaryChange in pulse rate from baselineBaseline (on arrival at the clinic) and 15 minutes after the procedure
Change in pulse rate, in beats per minute, calculated as the pulse rate measured 15 minutes after the procedure minus the baseline pulse rate measured on arrival at the clinic. Positive values indicate an increase from baseline.
SecondaryNumber of participants with adrenaline-related symptoms15 minutes and 30 minutes after the procedure
Number of participants reporting one or more symptoms potentially related to adrenaline, assessed by direct questioning: nervousness, anxiety, tremor or shakiness, flushing, sweating, light-headedness, tingling, or a sensation of a racing heart.
SecondaryIntra-procedural bleeding rated by the clinician using a 3-point scaleDuring the procedure
Bleeding during the procedure rated by the clinician performing the procedure on a 3-point scale based on visual estimation of blood loss and the need for any intervention to control bleeding: 1 = minimal, 2 = mild to moderate, 3 = moderate to severe. Scores range from 1 to 3; higher scores indicate more bleeding.
SecondaryArea of residual bleeding on the dressing padDay 3 after procedure
Area of blood staining on the adhesive dressing pad (transparent film dressing with absorbent pad), in square centimeters (cm²), measured from a photograph submitted by the participant through the hospital's LINE Official Account, using the known dimensions of the pad as a size reference. Larger areas indicate more post-procedure bleeding.
SecondaryParticipants' self-reported ecchymosis severityDay 7 post-procedure
Number of participants in each self-rated bruising severity category, based on perceived discoloration, pain, and appearance of the procedure site: None (no visible ecchymosis), Mild (slight discoloration or minimal pain), Moderate (noticeable discoloration and/or moderate discomfort), or Severe (significant discoloration and/or severe discomfort). Higher categories indicate worse bruising.
SecondaryParticipant satisfaction assessed using a 5-point Customer Satisfaction (CSAT) scaleDay 7 after procedure
Satisfaction with the procedure, including the appearance and healing of the procedure site, measured with the Customer Satisfaction Score (CSAT), a single 5-point rating ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction.
SecondaryChange in systolic and diastolic blood pressure from baselineBaseline (on arrival at the clinic) and 15 minutes after the procedure
Change in systolic and diastolic blood pressure, each in millimeters of mercury (mmHg), calculated as the value measured 15 minutes after the procedure minus the baseline value measured on arrival at the clinic. Systolic and diastolic values are reported separately. Positive values indicate an increase from baseline.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT07897201/registered